Clinical Trial Update: A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating INS365 ophthalmic solution for moderate to severe dry eye disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• INS365 Ophthalmic Solution (INS365)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Dry Eye Disease | Phase 2 | Status: COMPLETED